Abstract
The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A number of new agents are under investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies are under development to improve the detection rate of true non-metastatic and true metastatic patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc prostate cancer. However, the optimal sequencing of these treatments requires further investigation. The tolerability and side effects of the new drugs are also crucial issues to be discussed, as well as their activity against the disease. The uro-oncologic team has to stay updated about new medical therapies in order to be confident in debating with other professionals involved in prostate cancer decision making. Different points of view and nuances should be shared during multidisciplinary group discussions to achieve a balanced decision in disease management.
Keywords: Prostate cancer, androgen deprivation therapy, antiandrogens, prostate cancer unit, docetaxel, systemic therapy.
Current Cancer Drug Targets
Title:Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective
Volume: 21 Issue: 2
Author(s): Fabio Campodonico*, Marco Ennas, Silvia Zanardi , Ekaterini Zigoura, Arnoldo Piccardo, Luca Foppiani, Concetta Schiavone, Lino Squillace, Andrea Benelli, Andrea De Censi , Filippo Grillo-Ruggieri and Carlo Introini
Affiliation:
- Department of Abdominal Surgery, Urology, Galliera Hospital, Genova,Italy
Keywords: Prostate cancer, androgen deprivation therapy, antiandrogens, prostate cancer unit, docetaxel, systemic therapy.
Abstract: The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs and new treatment options. To update the background knowledge of shared uro-oncologic practice, we reviewed current statements and landmarks in systemic therapy. A number of new agents are under investigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies are under development to improve the detection rate of true non-metastatic and true metastatic patient. Five new drugs have shown to be effective on progression-free and overall survival in metastatìc prostate cancer. However, the optimal sequencing of these treatments requires further investigation. The tolerability and side effects of the new drugs are also crucial issues to be discussed, as well as their activity against the disease. The uro-oncologic team has to stay updated about new medical therapies in order to be confident in debating with other professionals involved in prostate cancer decision making. Different points of view and nuances should be shared during multidisciplinary group discussions to achieve a balanced decision in disease management.
Export Options
About this article
Cite this article as:
Campodonico Fabio *, Ennas Marco, Zanardi Silvia , Zigoura Ekaterini , Piccardo Arnoldo , Foppiani Luca , Schiavone Concetta , Squillace Lino , Benelli Andrea , De Censi Andrea , Grillo-Ruggieri Filippo and Introini Carlo , Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective, Current Cancer Drug Targets 2021; 21 (2) . https://dx.doi.org/10.2174/1568009620666201021163919
DOI https://dx.doi.org/10.2174/1568009620666201021163919 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Challenges and Persistent Questions in the Treatment of Trichomoniasis
Current Topics in Medicinal Chemistry Application of Genetic Polymorphisms in DNA Repair in the Prediction of Cancer Susceptibility and Clinical Outcome
Current Pharmacogenomics Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews Editorial (Hot Topic: Cytochrome P450s: New Insights and Relevance to Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology Preparation and Evaluation of in vitro Self-assembling HSA Nanoparticles for Cabazitaxel
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design Neuroglobin and Estrogen Receptors: A New Pathway of Cell Survival and Cell Death Balance
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Dual Function of Nitric Oxide in Carcinogenesis, Reappraisal
Current Drug Metabolism The Effects of Kisspeptin in Human Reproductive Function – Therapeutic Implications
Current Drug Targets Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics Adding to the Mix: Fibroblast Growth Factor and Platelet-Derived Growth Factor Receptor Pathways as Targets in Non – small Cell Lung Cancer
Current Cancer Drug Targets Hybrid Benzoxazole-Coumarin Compounds Induce Death Receptor-Mediated Switchable Apoptotic and Necroptotic Cell Death on HN-5 Head and Neck Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot topic: (Part I) Recent Trends in Anti-Cancer Drug Discovery (Guest Editor: Fazlul H. Sarkar)]
Mini-Reviews in Medicinal Chemistry Prospective Clinical Applications of CRF Peptide Antagonists
Current Molecular Pharmacology The SCF-type E3 Ubiquitin Ligases as Cancer Targets
Current Cancer Drug Targets